Circulating endocannabinoid levels, abdominal adiposity and related cardiometabolic risk factors in obese men

International Journal of Obesity

Volumn 31, Issue 4, 2007, Pages 692-699

  Cote M ^a,b   Matias, I ^c   Lemieux, I ^a   Petrosino, S ^c   Almeras N ^a   Despres J P ^a,b   Di Marzo, V ^c  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

^c CNR   (Italy)

Author keywords

2 arachidonoylglycerol; Anandamide; CB1 receptor; Endocannabinoid; Rimonabant

Indexed keywords

2 ARACHIDONOYLGLYCEROL; ADIPONECTIN; ANANDAMIDE; ENDOCANNABINOID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; TRIACYLGLYCEROL;

ABDOMINAL OBESITY; ADULT; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; COMPUTER ASSISTED TOMOGRAPHY; CONCENTRATION (PARAMETERS); CORRELATION ANALYSIS; HUMAN; INSULIN BLOOD LEVEL; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; OBESITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

ADIPONECTIN; ADIPOSITY; ADULT; ARACHIDONIC ACIDS; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BODY MASS INDEX; BODY SIZE; CHOLESTEROL; ENDOCANNABINOIDS; GLUCOSE TOLERANCE TEST; GLYCERIDES; HUMANS; INSULIN; INTRA-ABDOMINAL FAT; MALE; MIDDLE AGED; OBESITY; POLYUNSATURATED ALKAMIDES; RISK FACTORS; TRIGLYCERIDES;

EID: 33947606528     PISSN: 03070565     EISSN: 14765497     Source Type: Journal    
DOI: 10.1038/sj.ijo.0803539     Document Type: Article

References (30)

1. Bray GA, Bouchard C, James WPT (eds.) 1998 Handbook of Obesity. Marcel Dekker: New York.
2. Di Marzo V, Matias I. Endocannabinoid control of food intake and energy balance. Nat Neurosci 2005; 8: 585-589.
3. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005; 365: 1389-1397.
4. Fu J, Oveisi F, Gaetani S, Lin E, Piomelli D. Oleoylethanolamide, an endogenous PPAR-alpha agonist, lowers body weight and hyperlipidemia in obese rats. Neuropharmacology 2005; 48: 1147-1153.
5. Després JP, Golay A, Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005; 353: 2121-2134.
6. Sipe JC, Waalen J, Gerber A, Beutler E. Overweight and obesity associated with a missense polymorphism in fatty acid amide hydrolase (FAAH). Int J Obes Relat Metab Disord (Lond) 2005; 29: 755-759.
7. Lohman T, Roche A, Martorel R. The Airlie (VA) consensus conference standardization of anthropometric measurements.. In: Standardization of Anthopometric Measurements. Champaign: IL, 1988; 39-80.
8. van der Kooy K, Seidell JC. Techniques for the measurement of visceral fat: a practical guide. Int J Obes Relat Metab Disord 1993; 17: 187-196.
9. Behnke AR, Wilmore JH. Evaluation and regulation of body build and composition. In: Cliffs E, (ed). Englewood Cliffs, NJ: Prentice-Hall, 1974. pp 20-37.
10. Siri WE. The gross composition of the body. Adv Biol Med Phys 1956; 4: 239-280.
11. Ferland M, Després JP, Tremblay A, Pinault S, Nadeau A, Moorjani S et al. Assessment of adipose tissue distribution by computed axial tomography in obese women: association with body density and anthropometric measurements. Br J Nutr 1989; 61: 139-148.
12. Havel RJ, Eder H, Bragdon HF. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 1955; 34: 1345-1353.
13. Burstein M, Samaille J. Sur un dosage rapide du cholestérol lié aux beta-lipoprotéines du sérum. Clin Chim Acta 1960; 5: 609-610.
14. Richterich R, Dauwalder H. Zur bestimmung der plasmaglukose-konzentration mit der hexokinase- glucose-6-phosphat-dehydrogenase-methode. Schweiz Med Wochenschr 1971; 101: 615-618.
15. Desbuquois B, Aurbach GD. Use of polyethylene glycol to separate free and antibody- bound peptide hormones in radio-immunoassays. J Clin Endocrinol Metab 1971; 37: 732-738.
16. De Marchi N, De Petrocellis L, Orlando P, Daniele F, Fezza F, Di Marzo V. Endocannabinoid signalling in the blood of patients with schizophrenia. Lipids Health Dis 2003; 2: 5.
17. Després JP, Lamarche B. Effects of diet and physical activity on adiposity and body fat distribution:implications for the prevention of cardiovascular disease. Nutr Res Rev 1993; 6: 137-159.
18. Engeli S, Bohnke J, Feldpausch M, Gorzelniak K, Janke J, Batkai S et al. Activation of the peripheral endocannabinoid system in human obesity. Diabetes 2005; 54: 2838-2843.
19. Matias I, Gonthier MP, Orlando P, Martiadis V, De Petrocellis L, Cervino C et al. Adipo-insular hyperactivity of the endocannabinoid system in obesity and hyperglycaemia. J Clin Endocrinol Metab 2006; 91: 3171-3180.
20. Després JP, Lemieux I, Almeras N. Contribution of CB1 blockade to the management of high-risk abdominal obesity. Int J Obes Relat metab Disord (Lond) 2006; 30 (Suppl 1): S44-S52.
21. Sugiura T, Kobayashi Y, Oka S, Waku K. Biosynthesis and degradation of anandamide and 2-arachidonoylglycerol and their possible physiological significance. Prostaglandins Leukot Essent Fatty Acids 2002; 66: 173-192.
22. Di Marzo V, De Petrocellis L, Fezza F, Ligresti A, Bisogno T. Anandamide receptors. Prostaglandins Leukot Essent Fatty Acids 2002; 66: 377-391.
23. Valenti M, Viganò D, Cascio MG, Rubino T, Steardo L, Parolaro D et al. Differential diurnal variations of anandamide and 2-arachidonoyl-glycerol levels in rat brain. Cell Mol Life Sci 2004; 61: 945-950.
24. Osei-Hyiaman D, DePetrillo M, Pacher P, Liu J, Radaeva S, Batkai S et al. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest 2005; 115: 1298-1305.
25. Bouaboula M, Hilairet S, Marchand J, Fajas L, Le Fur G, Casellas P. Anandamide induced PPARgamma transcriptional activation and 3T3-L1 preadipocyte differentiation. Eur J Pharmacol 2005; 517: 174-181.
26. Koga D, Santa T, Fukushima T, Homma H, Imai K. Liquid chromatographic-atmospheric pressure chemical ionization mass spectrometric determination of anandamide and its analogs in rat brain and peripheral tissues. J Chromatogr B Biomed Sci Appl 1997; 690: 7-13.
27. Maccarrone M, Attina M, Bari M, Cartoni A, Ledent C, Finazzi-Agro A. Anandamide degradation and N-acylethanolamines level in wild-type and CB1 cannabinoid receptor knockout mice of different ages. J Neurochem 2001; 78: 339-348.
28. Lo Verme J, Fu J, Astarita G, La Rana G, Russo R, Calignano A et al. The nuclear receptor peroxisome proliferator-activated receptoralpha mediates the anti-inflammatory actions of palmitoylethanolamide. Mol Pharmacol 2005; 67: 15-19.
29. Blüher M, Engeli S, Kloting N, Berndt J, Fasshauer M, Batkai S et al. Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity. Diabetes 2006; 55: 3053-3060.
30. Richardson D, Ortori CA, Chapman V, Kendall DA, Barrett DA. Quantitative profiling of endocannabinoids and related compounds in rat brain using liquid chromatography-tandem electrospray ionization mass spectrometry. Anal Biochem in press (Epub ahead of print).